----
Current ValuationThe current P/E ratio is 112.64, above the reasonable range, cheaper than 6.14% of the time in the past 3 years, and the industry ranks 56/256, the industry Median -1.11.
112.64xP/E
$50.00Stock price
$0.44Earnings per share
112.64xP/E
Stock price$50.00Earnings per share$0.44
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -75.93x
- Typical range
- -121.57x–41.72x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
0295887116
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
| Name/Symbol | |||
|---|---|---|---|
MRKUSMerck | 112.95x | 81.16% | $358.41B |
CORTUSCorcept Therap | 171.02x | 148.29% | $9.28B |
HCMUSHutchmed China | 140.10x | 90.18% | $2.51B |
ETONUSEton Pharmaceuticals | 112.64x | 739.71% | $1.43B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
